Navigation Links
IMMUNE 3D® Expands Platform into New Disease Areas and Enters into Drug Discovery
Date:5/14/2019

IMMUNE 3D®, a privately held biotechnology company, announced today an expansion of their business strategy beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, matched autologous human T cell and tumor cell lines for IO discovery efforts.

IMMUNE 3D®’s proprietary platform aims to study factors that affect immune migration under complex physiological conditions. The company utilizes the platform in areas of drug target discovery, characterization, biomarker identification and drug delivery testing.

"The increase in preclinical research and development spending has steered biopharmaceutical companies towards finding cost-effective alternatives beyond traditional in vivo models,” said Vik Subbu, Founder and CEO of IMMUNE 3D®. “This has paved the way for ex vivo platforms such as IMMUNE 3D® to be used across areas of preclinical studies and translational drug development.“

"IMMUNE 3D® provides unique insights into the tumor immune-microenvironment. Importantly, this platform can assess the efficacy of a wide variety of therapeutic approaches beyond immune checkpoints including the evaluation of CAR-T therapies in solid tumors,” said Dr. Tonya Webb, Associate Professor of Microbiology and Immunology, at the University of Maryland, Baltimore and scientific advisor to IMMUNE 3D®.

IMMUNE 3D® aims to build on its extensive know-how and intellectual property to develop proprietary 3D models across broad immune-mediated diseases. The company has profiled targets that facilitate immune migration using its proprietary human T cell and tumor cell lines. These targets have the potential to serve as novel therapies across a variety of human disorders such as cancer, autoimmunity and infectious diseases.

About IMMUNE 3D®
IMMUNE 3D®'s proprietary platform, provides a unique and powerful tool to interrogate immunobiology of diseases. The Company’s mission is to shift the paradigm towards a wider use of 3D cultures in translational research while accelerating much needed drug candidates into the clinic. The company has assembled a network of key opinion leaders, academic partnerships, board members and industry scientists to advance its platform.
http://www.immune3d.com

Read the full story at https://www.prweb.com/releases/immune_3d_expands_platform_into_new_disease_areas_and_enters_into_drug_discovery/prweb16301402.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
2. Trivedi Global, Inc. and Maire Mayne Announce Research Results on the Impact of a Biofield Energy Treated Nutraceutical to Combat Inflammation and Autoimmune Disorders
3. Trivedi Global, Inc. and Dr. William Plikerd Announce Research on Impact of a Biofield Energy Treated Nutraceutical for Decreasing Inflammation and Autoimmune Disorders
4. Trivedi Global, Inc. with Inthirani Arul, Announce Research Results on the Impact of a Biofield Energy Nutraceutical for Reducing Inflammation and Autoimmune Disorders
5. IBM: Your Computer Can Help Scientists Study Connection Between Body Bacteria and Autoimmune Diseases
6. TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials
7. Oncimmune Signs Agreement with Leading Provider of Preventative Health Screenings
8. PNAS: From HIV to cancer, IL-37 regulates immune system
9. House fly genome reveals expanded immune system
10. Scientists question fundamental theory about education of immune police
11. Adolescent exposure to thc may cause immune systems to go up in smoke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2019)... ... September 20, 2019 , ... A new ... client demands for precision medicine products. The report, Lab Instrumentation Markets for ... 2018, the pharma/bio sector is the largest source of demand for laboratory instrumentation. ...
(Date:9/17/2019)... ... 17, 2019 , ... Dual-board certified periodontist and implant surgeon, ... of Implant Dentistry (ASID) Accreditation Courses. His lecture, “Understanding the Soft and Hard ... Modern Implant Dentistry course. Dr. Kim’s expertise comes from years of experience providing ...
(Date:9/11/2019)... ... ... Greenberg Traurig, LLP attorneys Stephen Baird , - Marcella C. ... 9-10, at the Hyatt Regency, Minneapolis. Greenberg Traurig is a founding sponsor of DeviceTalks, ... have been featured speakers at every DeviceTalks conference since 2011. , On Sept. 9, ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... ... 17, 2019 , ... Geneticure, Inc., a Rochester Minnesota company ... the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have ... for hypertension treatment. , The patent applies to Geneticure’s first pharmacogenomics test, ...
(Date:9/17/2019)... ... September 16, 2019 , ... When a lot of ... that allow for the complete 3D characterization of tissues through the use of confocal ... an imaging, image analysis and advanced cell culture focused contract research organization and today ...
(Date:9/17/2019)... ... 16, 2019 , ... MyBioGate Global Healthcare Innovation Competition Boston ... Boston, a forum organized by MyBioGate, Inc. and CUBIO Innovation Center that promotes ... process of evaluation, twelve companies out of over 200 applications were selected to ...
(Date:9/11/2019)... , ... September 09, 2019 , ... ... (IRT) for clinical trial randomization and drug supply chain management, today announced its ... the global life sciences industry. , “The integration between Veeva Vault EDC and ...
Breaking Biology Technology: